Jubilant Therapeutics Unveils Critical Phase 1/2 Findings for JBI-802 in Myeloproliferative Neoplasms #USA #Houston #Myeloproliferative_Neoplasms #Jubilant_Therapeutics #JBI-802
@newsen.bsky.socialExplore
@newsen.bsky.social
@newsen.bsky.socialJubilant Therapeutics Unveils Critical Phase 1/2 Findings for JBI-802 in Myeloproliferative Neoplasms #USA #Houston #Myeloproliferative_Neoplasms #Jubilant_Therapeutics #JBI-802